|
n/N (%) [n]
|
---|
Treatment
|
Low risk
|
Intermediate risk
|
High risk
|
---|
Temsirolimus 175/75 mg | 9/12 (75) | 11/18 (61) | 8/10 (80) |
[5 PR, 4 SD] | [1 CR, 5 PR, 5 SD] | [1 PR, 7 SD] |
Temsirolimus 175/25 mg | 10/13 (77) | 5/15 (33) | 5/15 (33) |
[2 PR, 8 SD] | [1 PR, 4 SD] | [5 SD] |
INV therapy | 4/11 (36) | 8/20 (40) | 0/9 (0) |
[4 SD] | [1 CR, 7 SD] | |
- *Disease assessment was based on radiographic review by independent radiologists and review of clinical data by independent oncologists; evaluable patients were those with tumor assessment available.
- MIPI = Mantle Cell Lymphoma International Prognostic Index; PR = partial response; SD = stable disease ≥8 weeks; CR = complete response; INV = Investigator’s choice.